title: [Second Consensus of the Chilean Society of Endocrinology and Diabetes about insulin resistance].
abstract: Insulin resistance is a prevalent condition commonly associated with unhealthy lifestyles. It affects several metabolic pathways, increasing risk of abnormalities at different organ levels. Thus, diverse medical specialties should be involved in its diagnosis and treatment. With the purpose of unifying criteria about this condition, a scientific-based consensus was elaborated. A questionnaire including the most important topics such as cardio-metabolic risk, non-alcoholic fatty liver disease and polycystic ovary syndrome, was designed and sent to national experts. When no agreement among them was achieved, the Delphi methodology was applied. The main conclusions reached are that clinical findings are critical for the diagnosis of insulin resistance, not being necessary blood testing. Acquisition of a healthy lifestyle is the most important therapeutic tool. Insulin-sensitizing drugs should be prescribed to individuals at high risk of disease according to clinically validated outcomes. There are specific recommendations for pregnant women, children, adolescents and older people.
authors.forename: Felipe
authors.initials: F
authors.lastname: Pollak
authors.forename: Verónica
authors.initials: V
authors.lastname: Araya
authors.forename: Alejandra
authors.initials: A
authors.lastname: Lanas
authors.forename: Jorge
authors.initials: J
authors.lastname: Sapunar
authors.forename: Marco
authors.initials: M
authors.lastname: Arrese
authors.forename: Carmen Gloria
authors.initials: CG
authors.lastname: Aylwin
authors.forename: Carmen Gloria
authors.initials: CG
authors.lastname: Bezanilla
authors.forename: Elena
authors.initials: E
authors.lastname: Carrasco
authors.forename: Fernando
authors.initials: F
authors.lastname: Carrasco
authors.forename: Ethel
authors.initials: E
authors.lastname: Codner
authors.forename: Erik
authors.initials: E
authors.lastname: Díaz
authors.forename: Pilar
authors.initials: P
authors.lastname: Durruty
authors.forename: José
authors.initials: J
authors.lastname: Galgani
authors.forename: Hernán
authors.initials: H
authors.lastname: García
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Lahsen
authors.forename: Claudio
authors.initials: C
authors.lastname: Liberman
authors.forename: Gloria
authors.initials: G
authors.lastname: López
authors.forename: Alberto
authors.initials: A
authors.lastname: Maíz
authors.forename: Verónica
authors.initials: V
authors.lastname: Mujica
authors.forename: Jaime
authors.initials: J
authors.lastname: Poniachik
authors.forename: Teresa
authors.initials: T
authors.lastname: Sir
authors.forename: Néstor
authors.initials: N
authors.lastname: Soto
authors.forename: Juan
authors.initials: J
authors.lastname: Valderas
authors.forename: Paulina
authors.initials: P
authors.lastname: Villaseca
authors.forename: Carlos
authors.initials: C
authors.lastname: Zavala
mesh_terms: D002677:Chile; D003697:Delphi Technique; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology*; D008019:Life Style; D008687:Metformin / Q000627:therapeutic use; D050177:Overweight / Q000150:complications; D011085:Polycystic Ovary Syndrome / Q000150:complications; D012307:Risk Factors; D012955:Societies, Medical / Q000592:standards
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin